Advertisement

Acute Myeloid Leukemia

  • Emil J. Freireich
Chapter

Abstract

Acute myeloid leukemia (AML) is a systemic disease that is “metastatic” from diagnosis; therefore, the problems typically associated with local and regional control, i.e., those associated with surgery and radiation therapy, do not play a role. Since virtually all patients who die as a result of a malignant disease die of systemic (metastatic) cancer, AML has served as a prototype illness for the development of systemic therapies, and advances in the control of this disease have been rapidly applied to the control of the more common metastatic cancers in man.

Keywords

Acute Myeloid Leukemia Combination Chemotherapy Acute Promyelocytic Leukemia Acute Myeloid Leukemia Patient United States Public Health 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Freireich EJ, Frei III E. Recent advances in acute leukemia. In: Moore CV, Brown EB, editors. Progress in hematology. New York: Grune and Stratton; 1964. p. 189–202.Google Scholar
  2. 2.
    Freireich EJ, Bodey GP, Hart JS, Rodriguez V, Whitecar JP, Frei III E. Remission induction in adults with acute myelogenous leukemia. In: Mathe G, editor. Recent results in cancer research, vol. 30. Berlin: Springer; 1970. p. 85–91.Google Scholar
  3. 3.
    Bodey GP, Hewlett JS, Coltman Jr CA, Rodriguez V, Freireich EJ. Therapy of adult acute leukemia with daunorubicin and L-asparaginase. Cancer. 1974;33:626–30.PubMedCrossRefGoogle Scholar
  4. 4.
    McCredie KB, Bodey GP, Freireich EJ, Gutterman JU, Hester JP, Drewinko B. Adult leukemia. In: Clark RL, Howe CD, editors. Cancer patient care at M.D. Anderson Cancer Center. Chicago: Year Book Medical Publishers; 1976. p. 165–97.Google Scholar
  5. 5.
    Bodey GP, Freireich EJ, McCredie KB, et al. Prolonged remissions in adults with acute leukemia following late intensification chemotherapy and immunotherapy. Cancer. 1981;47:1937–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA. 1982;248:2481–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Keating MJ, Cork A, Broach Y, et al. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res. 1987;11:119–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Freireich EJ. Four decades of therapy for acute myeloblastic leukemia. Leukemia. 1998;12 Suppl 1:S54–6.PubMedGoogle Scholar
  9. 9.
    Kantarjian H, O’Brien S, Cortes J, et al. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008;113(7):1933–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Special Medical Education, LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations